Literature DB >> 2707113

Importance of cardiovascular autonomic dysfunction in IDDM subjects with diabetic nephropathy.

E Zander1, B Schulz, P Heinke, E Grimmberger, G Zander, H D Gottschling.   

Abstract

Diabetic nephropathy (DNP) is associated with increased cardiovascular mortality. This may be contributed to by associated cardiovascular autonomic dysfunction (CAD). The aim of this study was to investigate the prevalence of CAD in patients with insulin-dependent diabetes mellitus (IDDM) at different stages of DNP. We studied patients with incipient DNP (group 1, n = 10), overt DNP (group 2, n = 20), renal insufficiency (group 3, n = 27), and end-stage renal failure (group 4, n = 12) and compared them with 30 IDDM patients without clinical signs of DNP (group 5) and with 17 nondiabetic controls (group 6). All groups were matched for age and diabetic groups were matched for duration of diabetes. Assessments of CAD included beat-to-beat variation during forced respiration, heart-rate response to standing, heart-rate response to Valsalva maneuver, basal heart rate, and blood pressure response to standing. Clinical evaluation included assessment of the history and an examination for peripheral polyneuropathy. We found mean impairment of heart-rate variation during respiration, in response to Valsalva maneuver, and in heart-rate response to standing in all diabetic groups compared with nondiabetic controls (P less than .01). Heart-rate responses differed significantly between patients with renal insufficiency (groups 3 and 4) and with other patient groups (group 5; P less than .01). CAD was shown to be more prevalent in patients with DNP, more so as DNP progresses. To some extent, it is already present in the early stages of DNP. CAD may be a contributory factor for increased cardiovascular mortality in patients with DNP.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1989        PMID: 2707113     DOI: 10.2337/diacare.12.4.259

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  8 in total

1.  [Cardiovascular risk factors in diabetic nephropathy].

Authors:  J Zimmermann; L Schramm; E Mulzer; E Heidbreder; H A Henrich; C Wanner
Journal:  Med Klin (Munich)       Date:  1997-02-15

2.  Diabetic autonomic neuropathy after pancreas and kidney transplantation.

Authors:  P Boucek; V Bartos; I Vanĕk; Z Hýza; J Skibová
Journal:  Diabetologia       Date:  1991-08       Impact factor: 10.122

3.  Circadian variation of blood pressure in patients with diabetic nephropathy.

Authors:  K W Hansen; M Mau Pedersen; S M Marshall; J S Christiansen; C E Mogensen
Journal:  Diabetologia       Date:  1992-11       Impact factor: 10.122

Review 4.  The management of diabetic neuropathy in CKD.

Authors:  Rodica Pop-Busui; Laurel Roberts; Subramaniam Pennathur; Mathias Kretzler; Frank C Brosius; Eva L Feldman
Journal:  Am J Kidney Dis       Date:  2009-12-30       Impact factor: 8.860

5.  Cardiovascular autonomic neuropathy associates with nephropathy lesions in American Indians with type 2 diabetes.

Authors:  Kevin M Wheelock; Mamta Jaiswal; Catherine L Martin; Gudeta D Fufaa; E Jennifer Weil; Kevin V Lemley; Berne Yee; Eva Feldman; Frank C Brosius; William C Knowler; Robert G Nelson; Rodica Pop-Busui
Journal:  J Diabetes Complications       Date:  2016-03-11       Impact factor: 2.852

6.  Cardiovascular Autonomic Neuropathy and Early Atherosclerosis in Adolescent Type 1 Diabetic Patient.

Authors:  Soha M Abd El Dayem; Ahmed A Battah; Abo El Magd El Bohy
Journal:  Open Access Maced J Med Sci       Date:  2015-12-13

7.  Systemic Amyloidosis and Cardiac Autonomic Neuropathy Associated with Waldenstrom's Macroglobulinemia.

Authors:  Aasems Jacob; Rishi Raj; Warren Walkow
Journal:  Case Rep Hematol       Date:  2017-06-13

8.  Lower risk of musculoskeletal pain among patients with end-stage renal disease treated by hemodialysis: A frequency-matched retrospective cohort study.

Authors:  Jie-Sian Wang; Jen-Huai Chiang; Heng-Jung Hsu
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.889

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.